MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T, European Research Initiative on CLL (ERIC) Haematologica. 2014 Aug,99(8):1285-91. doi: 10.3324/haematol.2013.101170.

A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?

Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, Preusser M, Greil R, Hopfinger G. Ann Hematol. 2015 Feb,94(2):345-6. doi: 10.1007/s00277-014-2162-5. Epub 2014 Jul 24.

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, the Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie und Therapie. Lancet. 2015 Apr 11,385(9976):1418-27. doi: 10.1016/S0140-6736(14)61469-0. Epub 2014 Dec 22.

A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and ГЋВІ(2) -microglobulin.

Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, Hackl H, Greil R, Pichler M, Egle A. Br J Haematol. 2015 Jan,168(2):239-45. doi: 10.1111/bjh.13116. Epub 2014 Sep 19.

Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility of chronic lymphocytic leukemia cells.

Hofbauer SW, Krenn PW, Ganghammer S, Asslaber D, Pichler U, Oberascher K, Henschler R, Wallner M, Kerschbaum H, Greil R, Hartmann TN. Blood. 2014 Apr 3,123(14):2181-8. doi: 10.1182/blood-2013-08-523563. Epub 2014 Feb 5.

The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by on-demand“ addition of plerixafor to granulocyte-colony-stimulating factor.“

Girbl T, Lunzer V, Greil R, Namberger K, Hartmann TN. Transfusion. 2014 Sep,54(9):2325-35. doi: 10.1111/trf.12632. Epub 2014 Mar 28.

C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.

Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M. Br J Cancer. 2014 Jul 8,111(1):55-60. doi: 10.1038/bjc.2014.277. Epub 2014 May 29.

Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.

Hopfinger G, Nösslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, Egle A, Greil R. Ann Hematol. 2014 Mar,93(3):459-62. doi: 10.1007/s00277-014-2009-0. Epub 2014 Jan 18.

Human immunodeficiency virus type 2 infections in Austria.

Taylor N, Kern JM, Prammer W, Lang A, Haas B, Gisinger M, Zangerle R, Egle A, Greil R, Oberkofler H, Eberle J. Wien Klin Wochenschr. 2014 Apr,126(7-8):212-6. doi: 10.1007/s00508-013-0493-1. Epub 2014 Jan 18.

Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.

Grössinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, Schmölzer J, Asslaber D, Hainzl S, Neureiter D, Egle A, Piñón-Hofbauer J, Hartmann TN, Greil R, Kerschbaum HH. Leukemia. 2014 Apr,28(4):954-8. doi: 10.1038/leu.2014.37. Epub 2014 Jan 20.